INTRODUCTION
Chemokines are proteins that participate in multitudes of normal and abnormal physiological processes, including inflammation, immunity, leukocyte chemotaxis and tumor metastasis (1) (2) (3) (4) . The Cysteine-X-Cysteine chemokines (CXCL) with Glutamineleucine-arginine motif (ELR+ CXCL) regulate physiological functions by binding and activating one or more seven transmembrane CXC chemokine receptors (CXCRs) (5) .
The CXCRs induce cell migration through the activation of a single or multiple members of structurally related GTP binding proteins, the G-proteins (6). The constitutive activation or over-expression of CXCL or CXCRs is linked to tumor growth and metastasis (7) (8) (9) .
The newest member of the seven CXCRs, CXCR7 (10) , binds to two chemokines, CXCL11 and CXCL-12 (SDF-1a) and dimerizes with CXCR4, a co-receptor for SDF-1a (11, 12) . This dual specificity receptor is up-regulated in many tumors. However, CXCR7
does not function like other CXCRs. CXCR7 binding to chemokines does not elicit intracellular calcium mobilization, or motility in normal cells, and thus its function has been intriguing (13). According to some reports expression of CXCR7 provides "proliferation and survival advantage and increased adhesion properties" (13, 14) . These reports did not elaborate however, the mechanism by which CXCR7 allows growth advantage to tumor cells. Elevated levels of CXCR7 in tumors suggest its expression and function may be regulated by other factors, such as inflammatory chemokines (e.g., independent growth, motility, invasion, and angiogenesis in prostate and other cancers via the distinct activation of two cognate receptors, CXCR1 and CXCR2 (16) (17) (18) . Here we demonstrate possible transregulation of CXCR4 and CXCR7 by IL-8 that could possibly contribute to increased proliferation and angiogenesis in CaP in a ligandindependent manner. Further, we report on the putative mechanism by which CXCR7 acts independent of its ligand-binding and stimulation of epidermal growth factor receptor (EGFR) phosphorylation, leading to mitogenic cascade and potentially a multitude of tumor promoting activities.
MATERIALS AND METHODS
Cell lines and culture methods: Acquisition and maintenance of all CaP cell lines (LNCaP, LAPC-4, and PC-3) were performed by routine procedures as described (19) .
In brief, LNCaP, PC3 were cultured in RPMI 1640 medium supplemented with fetal bovine serum (FBS, 10%) and gentamicin. LAPC-4 cells were maintained in Iscove's medium with 7.5 % FBS, 1 nM Dihydrotestosterone and gentamicin (16) . RWPE-1 cells were cultured in keratinocyte serum-free medium with gentamicin. All cell lines were obtained from an authenticated source (ATCC, Manassas, VA) and used within six months of resuscitation of original cultures. The cell lines used in the study were also authenticated for their origin by Genetica DNA Laboratories Inc. (Cincinnati, OH).
Global Gene expression analysis:
The global mRNA expression of IL-8 expressingLNCaP and LAPC-4 cells (LNCaP-IL8S, LAPC-4IL8S, respectively) was compared to vector-only transfectants (v), generated as reported before (16) , using Agilent cDNA expression array (Agilent Technologies, Santa Clara CA). These studies were conducted at University of Miami's DNA Micro-array Core Facility, which also performed the Bioinformatics analysis. To identify differentially expressed genes, mathematical "dyeswap" was performed on arrays and one-class significance analysis of microarrays (SAM) (20) was done with the following criteria: False discovery rate was less than 5% and the average fold change was greater than 2. SAM was run on the expressed genes, where at least 2 out of 4 replicates passed quality control.
Gene knockdown with siRNA and quantitative real time PCR (q-PCR): Cells cultured for 24h were transfected with gene-specific 21-mer siRNA sets (Smartpool siRNA, Dharmacon/Thermo Scientific Inc, Chicago, IL), using Dharmafect-2 transfection protocol (17) . Total RNA isolated from cells 48 h later was subjected to cDNA synthesis and q-PCR using iQ SYBR-Green Supermix (BioRad, Hercules, CA) and the primers described in Table S1 (Supplement). The mRNA levels were normalized to that of Cell proliferation assay and Cell cycle phase analysis: Cell proliferation and cell viability were determined by cell counting and MTT reduction assays, respectively (16) (17) . Cell cycle phase-fractionation was performed using Beckman-Coulter XCEL flow cytometer (21, 22) .
Immunoblotting: Expression of specific proteins in treated cells was analyzed by routine Western blotting. Presence of specific proteins on the western blot was detected using the ECL+ Kit (GE Health Science) and relative protein band intensities were quantified using densitometry (Gel Logic 2200, Care-Stream Instruments, Rochester, NY) (23).
Co-immunoprecipitation:
Cell lysates were prepared in RIPA buffer, centrifuged to obtain nuclei-free lysates, and immunoprecipitated (24) . In brief, lysates were incubated with anti-CXCR7 rabbit IgG (10 μg/ml, GeneTex)), with anti-EGFR Rabbit monoclonal antibody (Epitomics Inc., Santa Clara, CA) or normal rabbit IgG, overnight at 4 mRNA and p-EGFR proteins in tumor tissues were analyzed ex vivo, using tumor tissues collected at necropsy as described before (26) .
RESULTS
Malignant prostate tumor cells express high levels of CXCR7: As shown in Table 1 and compared to that of PC-3. Further, the level of CXCR4 mRNA was 5 to 10-fold lower than that of CXCR7 (Table 1) . Since many tumor cells co-express both ligands and receptors we measured the levels of the target chemokines (SDF-1a and CXCL11). The mRNA or protein expression of CXCL11 and SDF-1a in all CaP cells was insignificant ( Table 1) . (1 h) which, stabilized after 1 h with a sustained increase of 55% ( Fig. 1D-iii) . This rapid increase in CXCR7 mRNA following IL-8 addition was due to de-novo CXCR7 synthesis as it was completely abolished if incubated with 10ug/ml Actinomycin D (data not shown). Although external addition of IL-8 did not increase CXCR7 mRNA level in PC-3 cells, which endogenously produce IL-8, depletion of IL-8 in these cells by RNAi caused 73.3% reduction in CXCR7 mRNA, as compared to that with c-siRNA transfectants (Fig. 1B) . However, CXCR7 depletion did not Table 2 ). We validated by Q-PCR that LNCaP-V and LAPC-4V cells expressed 2-3 fold higher levels of CXCR4 mRNA than their IL-8S counterparts (Fig 1B ii) . Further, depletion of IL-8 in PC-3 cells by siRNA increased the expression of CXCR4 mRNA by 5-fold (Fig. 1Bii) . In addition, silencing of CXCR7 by siRNA in both LNCaP-V and PC-3 cells slightly increased CXCR4 mRNA (P>0.05), (Supplementary Fig. S1 ii). However, depletion of CXCR4 expression by siRNA in LNCaP cells increased CXCR7 mRNA by 2.5x (250%) but only modestly (~50%) in PC-3 cells (Fig S1iii) . (Fig 2B-inset) and cell counts on day 7 showed a significant ( 63%) reduction in cell density, compared to those in vector-only transfected cells (Fig. 2B) .
Global gene expression analysis of IL-8 secreting
Growth promoting activity of CXCR7 in CaP cells does not require its known ligands: Since CXCR7 depletion leads to decreased cell growth, we postulated that the activation of CXCR7 by its known ligand(s) is responsible for CXCR7-dependent cell proliferation. Since we could not detect autocrine production of CXCL11 or SDF-1a in
CaP cell cultures, we added CXCL-11, CXCL-12, or both, 50 ng/ml each, to cultures of PC-3, LNCaP and corresponding CXCR7-shRNA depleted clones (T74). We found little change (less than 3 % increase) in cell growth of PC3-V or PC3-T74 cells (that express CXCR4, but CXCR7 was depleted), after 7 days of culture with CXCL11 or SDF-1a, regardless of whether the cells were cultured in medium supplemented with or without FBS (10%) (Fig. 2C and Supplementary Fig. S2-ii & iii) .
Since CaP cells express both CXCR4 and CXCR7 (14) , and both share SDF1a as a ligand (13), we investigated whether CXCR4 depletion affects the PC-3 cells' growth.
Depleting CXCR4 mRNA by siRNA reduced CXCR4 mRNA in cells by >85% but did not affect cell proliferation when compared to control or CXCR7 siRNA transfectants (Fig.   2D) . However, silencing of both CXCR4 and CXCR7 expression together, reduced cell proliferation by 52.33 % ± 8.0 %, similar to a level of inhibition observed by depleting CXCR7 only (47.5 % ± 3.5%, Fig. 2D ). Further, this increased accumulation led to a significant decrease in S-phase (54% ± 6.5%) and in G2/M fractions (12 ± 2.5%) in PC-3 cultures. CXCR7 depletion in LNCaP cells led to a greater accumulation of G0/G1 (68% ± 2.5%), and decrease in S-and G2/M phase fractions (Fig. 3B) .
CXCR7 depletion decreases G1 to S transition-regulating proteins in CaP cells:
CXCR7 depletion by siRNA significantly decreased cell cycle-regulatory proteins, cyclin D1, cyclin E, and Rb (p-Rb) in both PC-3 and LNCaP cells. (Fig. 3C) . We found 40-fold decrease in cyclinD1, 1.5 to 2-fold decreases in Cdk-4, and 2 to 6.5-fold decreases in cyclinB1, in both CaP cells (Fig. 3C) and significantly increased P21 (11.5x in PC-3 and 15x-in LNCaP) protein levels, but none in P27P kip1 P protein levels.
An accumulation at G0/G1 and depletion of S-phase fraction in cultures depleted of CXCR7 could be due to the attenuation of MAP-kinase activity. Therefore, we measured the relative activation of Extra cellular signal-regulated receptor Kinase-1/2 (Erk1/2 ratio of p-Erk1/2) in c-siRNA and CXCR7 siRNA transfected PC-3 cells, using an ELISA.
Levels of p-Erk1/2 in CXCR7siRNA transfected cells were 31.70% ± 4% lower than that of c-siRNA transfected PC-3 (Fig. 3D) . To further validate the association of CXCR7 in Erk1/2 phosphorylation, we compared the Erk1/2 activity in PC-3-T74 cells with that of V transfectants. Again, p-Erk1/2 activity was markedly diminished in CXCR7 depleted cells (Fig. 3D) . Constitutive expression of CXCR7 in normal prostate epithelial cells increases cell proliferation: The CXCR7-expressing RWPE-1 cells (RWCX7) showed 23 % ± 3.5 % increase in cell growth (Fig. 4A) compared to the vector-only transfected RWPE-1 cells (RW-V).
CXCR7 stimulates EGFR phosphorylation:
Strong change in ERK1/2 activity upon CXCR7 depletion led us to test potential association of CXCR7 with growth factor receptors such as EGFR (32) . Indeed, we observed constitutively increased phosphorylation of EGFR and Erk1/2 in cells that express high level of CXCR7, such as RWCX7, LNCaP and PC-3 but not in RWPE-1 cells ( Fig. 4B ; also see Supplement Fig S3 (i & ii) for quantitation). CXCR7 depleted-cells showed lower levels of both p-EGFR and p-Erk1/2, as compared to those in c-siRNA transfectants (Fig 4C, see also Fig. 3D ).
Since CXCR7 expression stimulates cell proliferation without its ligand, we hypothesized that activation of EGFR and Erk1/2 phosphorylation may also be independent of CXCR7 ligands. We noticed increase in p-EGFR following stimulation with EGF, but not by SDF-1a, or CXCL11. As shown in Fig. 4D p-EGFR levels remained unchanged in cultures exposed to recombinant SDF-1a, or CXCL11 in both RWPE-1 and RWCXC7 cells, indicating ligand-independent role of CXCR7 in EGFR activation. In CXCR7 co-localizes with EGFR: Since expression of CXCR7 constitutively activates EGFR, we examined whether CXCR7 and EGFR co-localize or aggregate on plasma membrane (33) . We attempted to co-immunoprecipitate CXCR7 and EGFR from RWPE-1 or CaP cells, using anti-EGFR or anti-CXCR7 antibodies and non-ionic detergent solubilized cell lysates. As shown in Fig. 5A , and 5B, both molecules are immunoprecipitated by either anti-p-EGFR or anti-CXCR7 antibodies. We demonstrated further more p-EGFR in RWCX7 cells than that in RWPE-1V cells and CXCR7 overexpression increased phosphorylation of EGFR only at tyrosine 1110 but, not serine- ( Fig. 5C ). In addition, we performed confocal microscopy of LNCaP cells labeled with anti-EGFR (mouse anti-human IgG) and anti-CXCR7 (Rabbit anti-human IgG, GeneTex) antibodies followed by, fluorescent labeling with secondary antibodies labeled with Alexafluor 555 and Alexfluor488, respectively. The confocal micrographs although could not completely reveal whether the colocalization of CXCR7 and EGFR is inside or outside of the plasma membrane, showed several focal points at which the colocalization of two labeled antibodies were observed (see Supplementary Fig. S4 A-D).
Stable silencing of CXCR7 in CaP cells decreases tumor growth U in vivoU :
We characterized in vivo tumor growth of two CXCR7-depleted PC-3 sub-lines, T73 and T74 and compared their tumor growth with that of vector-only transfectants (v). The T73 and T74 cells express reduced levels of CXCR7 mRNA (by 61.23 %± 1.2% and 70.57% ± 2.2%), and proteins (50% and 75%), compared to PC-3V cells (Fig. 2) . We found a significant growth delay (> 35%) in both T73 and T74 tumors at the time of terminal measurement on day 42 (Fig. 6A) (Fig. 6B) . In addition, there was a significant decrease in p-EGFR as compared to total EGFR and cyclinD1 levels (Fig. 6C) , and VEGF mRNA (Fig. 6D) in T73 and T74 tissues as compared to PC-3V tumors, suggesting a link between tumor growth and decrease in angiogenesis, cell proliferation and cell cycle arrest resulting from CXCR7 depletion.
DISCUSSION
We report a novel mechanism of transregulation of chemokine/receptor-induced alteration in prostate tumor cells. We report four major observations: first, transient exposure or constitutive expression of a pro-inflammatory chemokine (IL-8) modulates non-target chemokine receptors (CXCR4 and CXCR7); second, although CXCR7 is a "decoy" receptor, it is highly modulated by IL-8, it is constitutively up regulated in tumor cells, extensively involved in cell proliferation; thereby participating in multiple protumorigenic activities. Third, CXCR7 is capable of modulating a variety of cellular functions without being activated by its identified ligands (CXCL-11 and SDF-1a), and four, CXCR7 is capable of stimulating cell proliferation, cell cycle progression and angiogenesis by coupling/co-localizing with EGFR. The last attribute may be responsible for increased tumor growth due to CXCR7 elevation.
The observation that extrinsic addition of IL-8 also results in a rapid rise in CXCR7 expression shows a dynamic interaction between IL-8 induced-intracellular signaling that results in transcriptional up regulation of CXCR7 and down regulation of CXCR4.
Further, an induction of CXCR7 by external IL-8 was more pronounced in cells that do not constitutively express IL-8, such as RWPE-1 and LNCaP, but not the cells (PC-3) that constitutively synthesize it (Fig. 1D) . This subdued response in PC-3 cells may be Fig. S5 ).
We showed that inhibition of IL-8 specific receptors, CXCR1 or CXCR2 can abrogate IL-8 induced CXCR7 up-regulation ( Supplementary Fig S1-iv) . This could be due to the co-regulation of CXCR2 by CXCR1, as we previously reported (26, 35) . Since receptor cross linking between CXCR1 and CXCR2 is required in IL-8 mediated intracellular signaling (36), it is likely that both receptors are essential for IL-8 mediated up regulation of CXCR7.
In contrast to CXCR7, IL-8 negatively regulates CXCR4 in CaP cells. When autocrine production of IL-8 was halted by RNAi, CXCR4 mRNA levels rose 4-fold in PC-3 cells, indicating, IL-8 down modulates the transcription of CXCR4 (Fig. 1Bii) . Although significantly lower than CXCR7, and therefore, these two receptors may play more complex roles in bone metastasis of CaP than previously thought (37).
Our findings have relevance to prostate cancer in men, where inflammation is considered a significant cause of disease progression (38) (39) (40) (41) (42) . Since IL-8 is a ubiquitous chemokine induced by acute or chronic inflammation, hypoxia, or necrosis, IL-8 is widely available in tumor microenvironment (43, 44) . Furthermore, we reported previously that (47), (48)]. Our results show that over-expression of CXCR7 alone is sufficient to increase cell proliferation in both normal and transformed cells ( Figs. 2A   and 4A) . Furthermore, increased CXCR7 expression also led to, constitutively and rapidly, EGF-induced increase of p-EGFR (Fig. 4B) . We found a stable complex formation between EGFR and CXCR7 in CaP cells that over express CXCR7, by two independent techniques (Fig.5A-C, and supplementary Fig S4 A-D) . 
